NL-OMON39290已完成2 期
An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer. - PAZEC
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Written informed consent.
- •2. Age * 18 years
- •3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- •4. Histologically or cytologically confirmed diagnosis of endometrial cancer.
- •5. Metastatic disease or locally advanced tumor not amenable to local therapy.
- •6. Documented progressive disease before enrolment.
- •7. Measurable lesions outside irradiated field or progressive measurable lesions in irradiated area.
- •8. Not eligible for hormonal therapy (because of negative hormone receptor/poor differentiation, or after failure of hormonal therapy)
- •9. Previous failure of chemotherapy, or refusal to undergo chemotherapy or chemo-naive patients not suitable for chemotherapy.
- •10. Adequate organ system function
排除标准
- •1. Prior malignancy.
- •Note: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
- •2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, with no radiological signs of progression and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug.
- •3. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or may affect absorption of investigational product.
- •4. Presence of uncontrolled infection.
- •5. Corrected QT interval (QTc) > 480 msecs using Bazett*s formula
- •6. History of major cardiovascular conditions within the past 6 months or poorly controlled hypertension, history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
- •7. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).
- •8. Evidence of active bleeding or bleeding diathesis.
- •9. Treatment with any of the following anti-cancer therapies: radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
研究者
相似试验
招募中
不适用
FASE II ONDERZOEK NAAR DEEFFECTIVITEIT VAN PAZOPANIB BIJ PATIËNTEN MET BAARMOEDERKANKER.Metastatic or locally advanced endometrial cancer not amenable to other therapyNL-OMON26478niversity Medical Center55
进行中（未招募）
1 期
A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer - MITO - 11platinum resistant or refractory ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033130EUCTR2009-016151-21-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE72
进行中（未招募）
1 期
An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancerPart I: Subjects with histologically or cytologically confirmed diagnosis of advanced solid tumours for which there is no standard therapy or for whom paclitaxel is standard therapy. Part II: Stage IIIB wet (with histologically- or cytologically-confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1 Level: LLT Classification code 10029521 Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2009-010571-24-GBGlaxoSmithKline Research & Development Limited
进行中（未招募）
不适用
A 12-Week Study of Eye Drops to Treat Wet Age-related Macular Degeneration (AMD)Age-related macular degeneration (AMD)MedDRA version: 14.0Level: PTClassification code 10025409Term: Macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2011-000243-24-DEGlaxoSmithKline Research & Development Ltd.30
已完成
2 期
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing BevacizumabLung CancerNCT01262820UNC Lineberger Comprehensive Cancer Center15